| Literature DB >> 24661822 |
Gabriella Lombardo, Maria Grazia Pennisi, Tiziana Lupo, Carmen Chicharro, Laia Solano-Gallego1.
Abstract
UNLABELLED: :Entities:
Mesh:
Substances:
Year: 2014 PMID: 24661822 PMCID: PMC3987822 DOI: 10.1186/1756-3305-7-120
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Signalment of dogs, number, distribution of papules and time of duration of lesions
| 1 | Mongrel | 6 | M | Multiple | Nose | Unknown |
| 2 | Boxer | 6 | M | Multiple | Abdomen | Unknown |
| 3 | Mongrel | 12 | F | 2 | Nose | 6 months |
| 4 | Labrador retriever | 11 | F | 4 | Bridge of the nose | 1 month |
| 5 | Mongrel | 8 | M | 4 | Inner surface of the pinna | Unknown |
| 6 | Mongrel | 8 | M | 3 | Inner surface of the pinna | Unknown |
| 7 | Mongrel | 3,5 | M | Multiple | Eyelid – Abdomen | Unknown |
| 8 | Mongrel | 4 | F | Multiple | Abdomen | 3 weeks |
| 9 | Mongrel | 4 | M | Multiple | Abdomen | 3 weeks |
| 10 | German Shepherd | 6 | F | Multiple | Inner surface of pinna - nose | 1 month |
| 11 | Cirneco dell’Etna | 17 | M | 4 | Medial aspect of the tibia | Unknown |
| 12 | Cirneco dell’Etna | 36 | M | 1 | Inner surface of the pinna | Unknown |
| 13 | Cane Corso | 18 | M | 1 | Abdomen | Unknown |
| 14 | Mongrel | 7 | F | 1 | Abdomen | Unknown |
| 15 | Mongrel | 7 | M | 1 | Abdomen | Unknown |
| 16 | Newfoundland | 12 | M | 2-3 | Inner surface of the pinna | 1 month |
| 17 | Rottweiler | 10 | M | Multiple | Eyelid | 1 month |
Figure 1Multiple papular lesions on the nose (case 4).
Figure 2Multiple papular lesions on the skin of abdomen (case 9 on the left and case 2 on the right).
Figure 3Multiple papular lesions on the inner surface of the pinna (case 5).
Figure 4Numerous extracellular amastigotes are seen in a hemodiluted sample from a papular lesion from case 10. Note one macrophage with intracytoplasmatic Leishmania amastigotes (Stain May-Grünwald-Giemsa, X1000).
Presence of confirmed by cytology, parasite culture, RT-PCR on single or multiple skin lesions from the dogs studied
| + | NP | NP | |
| + (a;b;c) | + (a;c); − (b); | + (a 60000); + (b 20000); + (c 50000); | |
| + (a; b) | - (a; b) | + (a 8000); + (b 20000); | |
| + (a; b; c) | NP | NP | |
| - | - | + (200) | |
| - | - | + (600) | |
| - | - | + (a 5120); + (b 10) | |
| + | - | - | |
| - | + | + (9500) | |
| + (a; b) | +(a; b) | + (a 10000); + (b 6500); | |
| NP | - | + (950) | |
| NP | NP | + (4000) | |
| NP | NP | + (8700) | |
| + | NP | + (1350) | |
| + | NP | + (2000) | |
| NP | NP | + (20) | |
| - | NP | + (800) |
+/−: presence or absence of Leishmania amastigotes by cytology or positive or negative by culture or PCR; NP: not performed; (l/s): Leishmania/sample; (a, b or c): results of different lesions sampled.
IFAT, RT-PCR and culture results in other tissues at the time of diagnosis and DTH test results at the time of diagnosis and/or during the follow-up
| | | | | |||||
|---|---|---|---|---|---|---|---|---|
| - | - | - | NP | NP | NP | 2,50# | 1,75# | |
| - | - | - | - | NP | NP | NP | NP | |
| - | - | - | - | NP | NP | 3,00# | 3,25# | |
| - | - | - | NP | - | NP | 1,60# | 1,75# | |
| 1:80 | - | - | - | + (5) | - | 2,25* | 1,15* | |
| - | - | - | - | + (10) | - | 1,25* | 2,00* | |
| - | - | - | - | - | - | NP | NP | |
| - | - | - | - | + (70) | + (3) | 1,50* | 1,25* | |
| - | - | - | - | + (20) | - | 1,00* | 0,00* | |
| - | - | - | - | - | - | 1,50* | 1,75* | |
| 1:160 | - | - | - | - | - | NP | NP | |
| - | - | - | NP | - | - | NP | NP | |
| 1:80 | - | - | NP | NP | NP | NP | NP | |
| 1:320 | - | - | NP | NP | NP | NP | NP | |
| 1:320 | - | - | NP | NP | NP | NP | NP | |
| - | - | + (6) | NP | NP | NP | NP | NP | |
| - | - | - | NP | NP | NP | NP | NP | |
| 5/17 (29.4%) | 0/17 (0%) | 1/17 (5.8%) | 0/9 (0%) | 4/9 (44.4%) | 1/8 (12.5%) | |||
+ positive; −: negative; NP: not performed; l/sample: Leishmania/sample; *DTH results upon clinical presentation and in some cases # at follow up.
Figure 5Haspb –PCR, PCR products were separated by electrophoresis on 2% agarose gels and stained with PronaSafe. 1.- Mr-100 bp; 2. and 3. - negative control; 4.- case 2 lesion a; 5.- case 2 lesion b; 6.- case 9; 7.- case 10 lesion a; 8.- case 10 lesion b.